explore -WSS

explore

author：hotspot 2025-10-01 10:35:44 - browse：1742

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： NYU radiologists take on the challenge of expensive MRI machines

explore

hotspot

WSS

Roivant's CEO is a star, but biotech's black hole persists

Is there really a nursing shortage in the U.S.?

In key trial, Verve's treatment lowers cholesterol levels in patients

Results on Novartis prostate cancer therapy could expand its use

Hospitals look to new technology to keep health care workers safe

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

explore

focus

Malaria cases in Florida and Texas: Here’s what you need to know

J&J lung cancer data amount to new salvo against AstraZeneca

The high cost of giving birth even with insurance

David Sabatini, ex

23andMe had bad news about my health. I wish a person had delivered it

David Sabatini, ex

Continuity nursing helped my family in our darkest PICU moments

Ransomware attacks on hospitals: Study outlines patient impact

Wildfire smoke exposes gaps in outdoor worker protections

Does good food count as health care? Study aims to find out

focus

Study on Amgen’s bispecific immunotherapy produces positive data

Astellas still sees hope in its gene therapy after four deaths

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout LOUD podcast: Live from the 2023 STAT Summit

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Readout Newsletter: Biotech news today

explore

hotspot

entertainment

knowledge